Skip to main content
Premium Trial:

Request an Annual Quote

Solexa Secures Remaining $24M of $32.5M Private Equity Financing from April

NEW YORK, July 14 (GenomeWeb News) - Solexa has secured the remaining $24 million in the second closing of its $32.5 million private equity financing, the company said on Tuesday.

 

The first closing of the funding round, completed in April, generated proceeds of $8.5 million from the sale of 2.1 million shares of common stock and 1.1 million warrants.

 

Under the terms of the second closing, Solexa raised $24 million by selling 6 million shares of common stock at $4 per share and issuing warrants to purchase up to 3 million shares of common stock at an exercise price of $5 per share.

 

The financing round was led by ValueAct Capital of San Francisco. Solexa's previous investors, Abingworth Management, Amadeus Capital Partners, Oxford Bioscience Partners, and SV Life Sciences invested $10.8 million in total at the second closing.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.